$166 Million is the total value of Asymmetry Capital Management, L.P.'s 29 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 103.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALKS | Buy | ALKERMES PLC | $11,515,000 | +53.8% | 373,382 | +22.3% | 6.92% | +34.5% |
| MDT | New | MEDTRONIC PLC | $10,496,000 | – | 83,737 | +100.0% | 6.31% | – |
| PODD | Buy | INSULET CORP | $10,440,000 | +31.4% | 36,732 | +26.9% | 6.28% | +14.9% |
| HOLX | Buy | HOLOGIC INC | $10,251,000 | +232.7% | 138,884 | +200.7% | 6.16% | +190.9% |
| SAGE | New | SAGE THERAPEUTICS INC | $10,152,000 | – | 229,117 | +100.0% | 6.10% | – |
| New | DICE MOLECULES HOLDINGS ORD | $9,012,000 | – | 275,165 | +100.0% | 5.42% | – | |
| ARNA | Buy | ARENA PHARMACEUTICALS INC | $8,933,000 | -7.9% | 150,001 | +5.5% | 5.37% | -19.5% |
| CYTK | New | CYTOKINETICS INC | $8,804,000 | – | 246,336 | +100.0% | 5.29% | – |
| QTRX | New | QUANTERIX CORP | $8,063,000 | – | 161,933 | +100.0% | 4.85% | – |
| PTCT | New | PTC THERAPEUTICS INC | $8,037,000 | – | 215,985 | +100.0% | 4.83% | – |
| MRTX | Sell | MIRATI THERAPEUTICS INC | $7,429,000 | -20.7% | 41,991 | -27.6% | 4.47% | -30.6% |
| AZN | Sell | ASTRAZENECA PLC-SPONS ADRadr | $6,981,000 | -33.8% | 116,242 | -34.0% | 4.20% | -42.1% |
| BLU | New | BELLUS HEALTH INC | $6,586,000 | – | 1,072,698 | +100.0% | 3.96% | – |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $6,245,000 | +116.5% | 653,976 | +118.5% | 3.75% | +89.3% |
| ISEE | New | IVERIC BIO INC | $5,772,000 | – | 355,396 | +100.0% | 3.47% | – |
| KYMR | Sell | KYMERA THERAPEUTICS INC | $5,232,000 | -12.6% | 89,071 | -27.8% | 3.14% | -23.5% |
| BAX | New | BAXTER INTERNATIONAL INC | $4,952,000 | – | 61,570 | +100.0% | 2.98% | – |
| AVDL | Buy | AVADEL PHARMACEUTICALS PLCadr | $4,649,000 | +72.8% | 474,368 | +18.7% | 2.80% | +51.2% |
| ACRS | Sell | ACLARIS THERAPEUTICS INC | $4,351,000 | -21.5% | 241,701 | -23.5% | 2.62% | -31.4% |
| KURA | New | KURA ONCOLOGY INC | $3,639,000 | – | 194,309 | +100.0% | 2.19% | – |
| RNA | New | AVIDITY BIOSCIENCES INC | $3,106,000 | – | 126,116 | +100.0% | 1.87% | – |
| PMVP | Sell | PMV PHARMACEUTICALS INC | $3,006,000 | -13.5% | 100,882 | -0.9% | 1.81% | -24.4% |
| HZNP | New | HORIZON THERAPEUTICS PLC | $2,733,000 | – | 24,949 | +100.0% | 1.64% | – |
| ITOS | Sell | ITEOS THERAPEUTICS INC | $1,547,000 | -1.5% | 57,286 | -6.5% | 0.93% | -13.9% |
| New | AVALO THERAPEUTICS INC | $1,165,000 | – | 534,621 | +100.0% | 0.70% | – | |
| GMTX | New | GEMINI THERAPEUTICS | $1,148,000 | – | 284,079 | +100.0% | 0.69% | – |
| RGLS | Sell | REGULUS THERAPEUTICS INC | $968,000 | -18.0% | 1,401,491 | -3.4% | 0.58% | -28.2% |
| BLSA | Sell | BCLS ACQUISITION CORP- CL A | $730,000 | -16.8% | 73,306 | -12.0% | 0.44% | -27.2% |
| LRMR | New | LARIMAR THERAPEUTICS INC | $403,000 | – | 34,943 | +100.0% | 0.24% | – |
| GLTO | Exit | GALECTO INC | $0 | – | -60,968 | -100.0% | -0.21% | – |
| VERV | Exit | VERVE THERAPEUTICS ORD | $0 | – | -24,790 | -100.0% | -1.03% | – |
| MCRB | Exit | SERES THERAPEUTICS INC | $0 | – | -63,259 | -100.0% | -1.04% | – |
| GRPH | Exit | GRAPHITE BIO ORD | $0 | – | -51,039 | -100.0% | -1.08% | – |
| BIO | Exit | BIO-RAD LABORATORIES-A | $0 | – | -2,979 | -100.0% | -1.32% | – |
| FBRX | Exit | FORTE BIOSCIENCES INC | $0 | – | -66,390 | -100.0% | -1.54% | – |
| ARGX | Exit | ARGENX SE - ADRadr | $0 | – | -8,104 | -100.0% | -1.68% | – |
| GH | Exit | GUARDANT HEALTH INC | $0 | – | -24,443 | -100.0% | -2.09% | – |
| ASLN | Exit | ASLAN PHARMACEUTICALS LT-ADRadr | $0 | – | -1,194,070 | -100.0% | -2.71% | – |
| BDSX | Exit | BIODESIX INC | $0 | – | -381,378 | -100.0% | -3.46% | – |
| MREO | Exit | MEREO BIOPHARMA GROUP PL-ADRadr | $0 | – | -1,618,328 | -100.0% | -3.53% | – |
| EPIX | Exit | ESSA PHARMA INC | $0 | – | -212,525 | -100.0% | -4.18% | – |
| ADPT | Exit | ADAPTIVE BIOTECHNOLOGIES | $0 | – | -168,172 | -100.0% | -4.72% | – |
| JAZZ | Exit | JAZZ PHARMACEUTICALS PLC | $0 | – | -52,702 | -100.0% | -6.44% | – |
| SHC | Exit | SOTERA HEALTH CO | $0 | – | -421,341 | -100.0% | -7.02% | – |
| CNC | Exit | CENTENE CORP | $0 | – | -164,489 | -100.0% | -8.25% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-04
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CENTENE CORP | 21 | Q4 2021 | 10.7% |
| UNITEDHEALTH GROUP INC | 21 | Q4 2021 | 7.2% |
| AMICUS THERAPEUTICS INC | 20 | Q4 2021 | 8.0% |
| PTC THERAPEUTICS INC | 19 | Q3 2021 | 13.8% |
| AERIE PHARMACEUTICALS INC | 16 | Q4 2019 | 9.9% |
| JAZZ PHARMACEUTICALS PLC | 15 | Q2 2021 | 10.2% |
| BIO-RAD LABRATORIES | 13 | Q2 2021 | 6.3% |
| NEVRO CORP | 12 | Q3 2018 | 7.2% |
| NEUROCRINE BIOSCIENCES INC | 12 | Q4 2018 | 6.5% |
| NUCANA PLC-ADR | 12 | Q4 2020 | 2.6% |
View Asymmetry Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-01-19 |
| 13F-HR | 2021-11-04 |
| 13F-HR | 2021-07-28 |
| 13F-HR | 2021-05-11 |
| 13F-HR | 2021-02-11 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-06 |
| 13F-HR | 2020-05-13 |
| 13F-HR | 2020-02-12 |
| 13F-HR | 2019-11-12 |
View Asymmetry Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.